90 likes | 118 Views
Exovene : Treatment of Testicular Cancer. Chylee Martin and Helaina Lefler. Young adult males between the ages of 18 and 40 who have been diagnosed with testicular cancer. Population. Risks H air loss N ausea/vomiting Dizziness Lower levels of testosterone or decreased sperm levels
E N D
Exovene: Treatment of Testicular Cancer Chylee Martin and Helaina Lefler
Young adult males between the ages of 18 and 40 who have been diagnosed with testicular cancer Population
Risks • Hair loss • Nausea/vomiting • Dizziness • Lower levels of testosterone or decreased sperm levels • Benefits • Treatment of cancer • Reduce side effects, promote tumor shrinkage, completely eradicate testicular cancer Potential Risks and Benefits
Delivery method: ointment applied directly to testicles • The treatment will target cancerous cells of the testicles that have increased metabolisms • The nanoparticles with competitive inhibitors for a cellular respiration enzyme will attach to and enter the cells and their mitochondria Description of Treatment
Nanoparticles with competitive inhibitors will inhibit the hexokinase enzyme that catalyzes the phosphorylation of glucose, therefore inhibiting cellular respiration and metabolism • The competitive inhibitor will bind to the hexokinase active site, therefore inhibiting cellular respiration • The cells will then die because they will be unable to make ATP and will not be able to survive Description of Treatment
Goals: to determine… • The efficacy of the treatment • Any side effects the treatment presents • Proper dosages • Hypothesis: the Exovene treatment will successfully kill the cancerous cells by inhibiting cellular respiration and eradicate the testicular cancer • This treatment is better than previous treatments because it can be applied directly to the affected area, will not affect any surrounding healthy cells, and will cause less discomfort for the patient. Trial Objectives and Purpose
Double-Blind Trial • One randomized group of 50 patients will receive one treatment, while the second randomized group of 50 patients will receive another treatment (based off strata of similar individuals) • Treatments will randomly be assigned to each group • One group receives Exovene treatment • The other group receives a placebo Trial Design
Criteria: • Male • Must be within age group (21 to 40 years old) • Must be diagnosed with testicular cancer Selection of Subjects
Do not use except for the intended medical purpose • Do not allow anyone else to use the ointment • Use only on the patient’s testicles • Do not go over or under in dosage (use with proper prescription) Assessment of Safety